Core Viewpoint - The understanding of "growth" in the orthopedic high-value consumables industry is shifting towards maintaining profit and cash flow under continuous price pressure, rather than just revenue expansion [2]. Group 1: Performance Forecast - Dabo Medical expects a net profit attributable to shareholders of 580-610 million yuan for 2025, representing a year-on-year growth of 62.55%-70.96% [2][3]. - The net profit after deducting non-recurring gains and losses is projected to be 455-485 million yuan, with a year-on-year increase of 59.42%-69.93% [2][3]. - The basic earnings per share are estimated to be between 1.43 and 1.50 yuan, compared to 0.86 yuan in the previous year [3]. Group 2: Consistent Performance - The performance in 2025 is not a result of year-end rush but rather a gradual realization throughout the year [4][6]. - In the first three quarters, the company achieved a net profit of 425 million yuan, a year-on-year increase of 77.03%, laying a solid foundation for the annual performance forecast [4]. Group 3: Profit Growth vs. Revenue Growth - The company's revenue growth of 22.69% in the first three quarters is not particularly outstanding, but profit growth significantly outpaces revenue growth [7][8]. - The increase in operating profit and net profit attributable to shareholders is notably higher than revenue growth, indicating improved operational efficiency and cost control [8]. Group 4: Profit Structure and Cash Flow - The projected growth in net profit after deducting non-recurring items aligns closely with the overall net profit growth, suggesting that the profit increase is primarily driven by core business improvements rather than one-off items [9]. - The net cash flow from operating activities reached 468 million yuan in the first three quarters, significantly exceeding the profit growth rate [10][11]. Group 5: Structural Realization in a Normalized Environment - The performance forecast for 2025 reflects a structural realization, characterized by profit growth outpacing revenue growth and simultaneous improvement in net profit and cash flow [12]. - This indicates that the company has adapted to the normalized procurement environment and completed internal adjustments [12]. Group 6: Changing Growth Dynamics - The noteworthy aspect of the performance forecast is the change in growth dynamics, emphasizing profit elasticity, cash flow improvement, and gradual adaptation of the operational structure to the new environment [14].

Core Viewpoint - SonoMotion's Break Wave™ system represents a significant advancement in kidney stone treatment, being the first FDA-approved non-invasive ultrasound device that does not require anesthesia, allowing for outpatient procedures [2][3]. Treatment Scenario Reconstruction: From Operating Room to Outpatient - Break Wave™ is categorized as an Extracorporeal Lithotripsy system, enabling treatment in regular clinics without the need for anesthesia or ureteral stent placement, allowing patients to eat normally and return home post-treatment [3]. Technical Pathway Breakdown: Low-Pressure Focused Ultrasound Achieving "Fragment + Clear" - SonoMotion's technology is based on low-pressure focused ultrasound combined with real-time imaging guidance, consisting of two complementary systems: Break Wave™ for non-invasive stone fragmentation and Stone Clear™ for post-operative stone clearance [6][7]. Clinical and Compliance Foundation: Evidence Structure Behind Approval - The FDA approval of Break Wave is supported by multiple clinical and preliminary research results, including multi-center clinical trials in the U.S. and Canada, and a $2.2 million grant from the NIH [10]. Company Positioning: A Startup Aiming to Rewrite Stone Fragmentation Logic - Founded in 2014, SonoMotion focuses on ultrasound technology for treating urinary system diseases, aiming to transform kidney stone treatment from invasive surgical procedures to outpatient interventions, thereby reducing costs and patient wait times [13]. Conclusion - SonoMotion is not positioning itself as a traditional stone fragmentation device manufacturer but is redefining the clinical landscape, resource allocation, and patient experience in kidney stone treatment. The FDA approval marks a critical phase for the company as it transitions from clinical validation to commercial implementation [14].

在硬科技行业中，初创企业活下去靠现金流，活得好靠战略定力。但研发的长期投入与现金流的现实 压力会产生碰撞，创业者往往顾此失彼，难以找准平衡点。如何在确保生存的同时不丢失未来？这不 仅是技术或资本的问题，更是关乎创业者自身的节奏感、韧性与战略考验。 1月15日，在第18届创业邦年会暨创业邦100未来独角兽大会上， 普华永道中国科创与民营企业服 务主管合伙人张勤、追梦空天CEO蔡文宽、因时机器人创始人兼CEO蔡颖鹏、科塞尔医疗创始人兼 CEO胡清、京东政企业务成长型业务副总经理青春雷、国信医药首席执行官宋伟、纵苇科技联合创始 人兼COO许卓群、智平方联创、董事、副总裁张鹏 ，展开了一场深度圆桌对话。围绕"回归商业， 回归'现金流为王'"这一主题，嘉宾们探讨在长周期、高投入的创业路上，如何平衡研发与现金流、 如何实现降本增效。 以下为上述圆桌的对话实录，由创业邦整理。 在研发与现金流的平衡中 走稳长期主义的每一步 张勤： 让我们回到商业最核心、也最现实的问题——现金流。在当下，产业的共识愈发清晰：活下 去，并且健康地生长。今天我们邀请了多位高投入、高壁垒赛道的嘉宾。在开始之前，请各位简短介 绍一下自己的企业和情况。 ...

（文章来源：证券时报网） 数据宝统计，截至09:57，达安基因成交额15.12亿元，创2022年5月25日以来新高。最新股价上涨 7.99%，换手率14.16%。上一交易日该股全天成交额为3.56亿元。 据天眼查APP显示，广州达安基因股份有限公司成立于1988年08月16日，注册资本140344.6032万人民 币。（数据宝） ...

Market Overview - The market experienced a mild increase this week, with the average daily trading volume in the Shanghai and Shenzhen markets significantly declining, yet remaining at a historical high of approximately 2.7 trillion [1][3] - A-shares have escaped short-term emotional fluctuations and returned to a rational operational track, supporting a steady and gradual bull market trend [1][3] - Market activity remains high, indicating numerous investment opportunities [1][3] Investment Strategy - The company anticipates that the market will exhibit a "slow bull" characteristic until the Chinese New Year, with rapid theme rotations [1][3] - A long-term investment strategy is recommended, focusing on selecting stocks with favorable long-term trends while avoiding short-term speculation [1][3] Long-term Focus Areas 1. The repeated TACO (Trade Adjustment and Cooperation Agreement) by the U.S. may lead countries to accelerate self-sufficiency in defense, resources, finance, and supply chains, intensifying resource competition and indicating an upward cycle for commodities [1][3] 2. The intensifying global technology competition is driving the domestic strategy for technological self-reliance, presenting dual development opportunities in the A-share technology growth sector through domestic substitution and industrial upgrading [1][3] Industry Performance - In the past week, the construction materials, oil and petrochemicals, and steel industries performed notably well, with respective increases of +9.23%, +7.71%, and +7.31% [14]

胡海研究员（中） 与团队成员交流。中国科学院杭州医学研究所 供图 一方面，早期肺癌多无症状，多数患者就诊时已属晚期；另一方面，肺部小结节大多为良性，让不 少人陷入"结节焦虑"，甚至出现过度诊疗。如何破解肺癌早期诊断的这一困境广受关注。 人体生物系统极为复杂，要精准找到肺癌特异性标志物如同"大海捞针"。研发团队攻克多项技术难 关，利用百万级癌症组织文库和多模态高通量筛选技术，结合合成生物学方法，重组表达400余种肺癌 早期关键蛋白，最终通过自主开发的液态悬浮芯片技术和人工智能算法，筛选出13种诊断性能最优的标 志物组合，其中8种为全新发现的标志物，远超现有临床应用水平。 应用优势获多中心临床试验印证 为让实验室成果落地应用，研发团队还突破生产工艺瓶颈，通过定制化蛋白标签设计、优化缓冲液 配方等创新，并攻克检测干扰、批间差异大等问题。引入冻干工艺后，冷藏条件下，试剂盒产品货架期 延长至12个月，且所有核心原料均实现自主生产，保障了产能与稳定性。 聚焦这一痛点，他领导项目团队从2016年起锁定肿瘤自身抗体检测技术持续攻关研发，该技术能捕 捉早期肺癌的"分子信号"，在癌细胞数量极少、病情隐匿时就能发出预警，非常适合早 ...

Core Insights - The research team led by Hu Haike from the Hangzhou Institute of Medicine has developed the world's first diagnostic kit for distinguishing between benign and malignant lung nodules, which has received regulatory approval as a Class III medical device in China [1][2] - Lung cancer remains the most prevalent and deadly cancer in China, with approximately 150 million people suffering from lung nodules, of which over 95% are benign [1][2] Group 1 - The diagnostic kit is expected to significantly improve early detection rates of lung cancer, addressing a critical challenge in reducing lung cancer mortality [2][3] - The team has focused on the early diagnosis of lung cancer since 2016, utilizing a large cancer tissue library and advanced screening technologies to identify specific biomarkers [2] - The kit has shown a sensitivity of over 65% for early lung cancer detection, with an accuracy rate exceeding 85% when used alongside low-dose spiral CT for atypical small nodules [2] Group 2 - The kit is anticipated to be launched in the market after the Spring Festival, providing essential support for China's "Healthy China 2030" cancer early screening strategy [3]

Group 1 - The core point of the news is that Lidman experienced a decline of 5.06% in its stock price, reaching 7.31 CNY per share, with a trading volume of 73.24 million CNY and a turnover rate of 1.81%, resulting in a total market capitalization of 3.977 billion CNY [1] - Lidman is based in Beijing Economic and Technological Development Zone and was established on November 5, 1997, with its listing date on February 16, 2012. The company's main business includes in vitro diagnostic reagents (67.84%), diagnostic instruments (14.17%), other services (13.21%), and biochemical raw materials (4.78%) [1] Group 2 - From the perspective of Lidman's top ten circulating shareholders, a fund under Yongying Fund ranks among them. The Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 2.0113 million shares, which accounts for 0.37% of the circulating shares. The estimated floating loss today is approximately 784,400 CNY [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 3.677 billion CNY. Year-to-date returns are 9.26%, ranking 1688 out of 5548 in its category, while the one-year return is 14.72%, ranking 3691 out of 4285. Since its inception, it has incurred a loss of 46.69% [2] Group 3 - The fund manager of the Medical Device ETF (159883) is Chu Kefa, who has been in the position for 2 years and 168 days. The total asset scale of the fund is 5.205 billion CNY, with the best fund return during the tenure being 103.17% and the worst being -30.27% [3]

Group 1 - The stock of MicroPort Scientific Corporation-B (02160.HK) has decreased by 7% [1] - As of the time of reporting, the stock price is at 0.93 HKD [1] - The trading volume reached 3.3167 million HKD [1]

【九安医疗】2025业绩预告：主业稳健，利润大幅增长主要系资产管理贡献 业绩概况： 2025全年：归母净利润20.2–23.5亿元（同比+21.05%~+40.83%）；扣非净利润20.7–24亿元（同比 +23.18%~+42.81%）。 2025Q4：归母净利润4.31–7.61亿元（同比+43.60%~+153.57%）；扣非净利润4.92–8.22亿元（同比+62.07%~+ 业绩概况： 2025全年：归母净利润20.2–23.5亿元（同比+21.05%~+40.83%）；扣非净利润20.7–24亿元（同比 +23.18%~+42.81%）。 2025Q4：归母净利润4.31–7.61亿元（同比+43.60%~+153.57%）；扣非净利润4.92–8.22亿元（同比 +62.07%~+170.77%）。 简评： 1）净利润同比增长主要系资管业务大类资产配置表现良好。 2）试剂盒类产品作为常规家用上呼吸道病毒筛查工具，以及家用医疗健康电子产品市场需求持续稳定。 【九安医疗】2025业绩预告：主业稳健，利润大幅增长主要系资产管理贡献 ...